Arsenic trioxide as primary treatment in acute promyelocytic leukemia
<jats:p> 16533 </jats:p><jats:p> Acute Promyelocytic Leukemia (APL) is a separate, distinct and biologically unique subset of Acute Myelogenous Leukemia (AML). The affordability of ATRA is detrimental for its use especially in the developing world. The use of Arsenic trioxide (As2O...
| Journal Title: | Journal of Clinical Oncology |
|---|---|
| Authors and Corporations: | |
| In: | Journal of Clinical Oncology, 24, 2006, 18_suppl, p. 16533-16533 |
| Type of Resource: | E-Article |
| Language: | English |
| published: |
American Society of Clinical Oncology (ASCO)
|
| Subjects: |